A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
Status:
Terminated
Trial end date:
2011-08-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the difference in objective response rates between
each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus
bevacizumab arm (Arm C) in subjects with advanced non-squamous NSCLC.